BerGenBio will test its lead candidate, BGB324, in combination with Keytruda to stop advanced breast cancer in its tracks - writes labiotech.eu.
BerGenBiodevelopsAXL kinase inhibitorsfor multiple cancer indications. The company dosed its first patient in a Phase II trial to test its lead candidate,BGB324, in combination withKeytruda– an antibody that interferes with the growth and spread of cancer cells. It‘s been a good year for the Norwegian biotech, which raised€43.55Mto beat the record biotech IPO on the Norwegian Stock Exchange and its market cap now stands at NOK 1.1B (€120M).
AXL kinase is a receptor found ontumor cells and its activation drivesepithelial-mesenchymal transition. This causes aggressive cancer traits like cell proliferation, immune evasion and migration. BerGenBio scientists were the first to recognize the receptor ‘ s importance to cancer, and BGB324 is the only small molecule AXL kinase inhibitor in clinical development.
Although breast cancer 5-year survival is promising at early stages, it drops to15%in advanced patients.20%of breast cancers are resistant to 3 common hormone therapies. This limits treatment options tointense chemotherapy, but BerGenBio could offer a solution. It’s worth keeping an eye out forTransgene‘soncolytic virus vaccine andGenenta‘s genetically modified stem cells, which are also active in the field.
Read more news of Oslo on our site.